Abbott Laboratories stock: Quote update after pipeline report
Published on 11/16/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline updates remain in focus
- Abbott announced new diagnostic and cardiac-device developments on November 10.
- The Panbio home test expands respiratory testing in Canada, while the UltiSynq lead adds a cardiac-device milestone.
- Investors are watching how the product pipeline translates into commercial growth.
Abbott Laboratories stock traded at 99.78 euros on Lang & Schwarz at 16:08 CET on Monday, November 16, 2026. The quote compares with 98.48 euros in the Abbott article published on November 14, a difference of 1.32 percent since that publication.
The latest market context includes product announcements from November 10. A Longbridge weekly review reported that Abbott launched its Panbio COVID-19 and flu A/B self-test in Canada and announced FDA approval and CE marking for an implantable cardioverter-defibrillator lead.
Recent pipeline developments
The Panbio test targets at-home detection of COVID-19 and influenza A and B. The review said the product was being rolled out through more than 1,800 Canadian pharmacies, giving the diagnostics portfolio a broader consumer reach.
The UltiSynq lead is designed to support conduction-system pacing and defibrillation. For investors, the two announcements point to different commercial profiles: a consumer diagnostic product with pharmacy distribution and a regulated cardiac device aimed at specialist care.
What investors watch next
Abbott's pipeline remains central to the investment case alongside the company's established medical-device, diagnostics and nutrition businesses. The near-term question is how quickly new approvals and launches contribute to revenue and offset pressure in slower-growth areas.
The broader US healthcare market context is available in Current market reports.
More news and analyses on Abbott Laboratories stock.
Abbott Laboratories overview
- Company: Abbott Laboratories
- ISIN: US0028241000
- US ticker: ABT
- Quoted price: 99.78 euros on Lang & Schwarz, November 16, 2026, 16:08 CET
